Dr. Alexandros Bouras received his Medical Degree (MD) from the University of Athens Medical
School in Athens, Greece. He completed his residency in General Surgery at
Metaxa Cancer Hospital in Piraeus, Greece, and his residency in Neurological Surgery at Tzanio
General Hospital in Piraeus, Greece. He is currently a Senior Research Scientist
and the Lab Manager of the Brain Tumor Nanotechnology Laboratory at the
University of Pittsburgh Medical Center Hillman Cancer Center in the Department
of Neurosurgery. Dr. Bouras’ main research interests focus on the application of magnetic hyperthermia therapy and photodynamic
therapy for the targeted imaging and therapy of patient-based glioma models
both in cell culture and rodent models. Moreover, he is actively
investigating the delivery of therapeutics in the brain by convection-enhanced
delivery, as well as the use of focused ultrasound for either the sonodynamic
therapy of malignant brain tumors or blood–brain barrier opening for the enhanced
systemic delivery of therapeutics in the brain. Finally, he is heavily involved
in the study of combination therapies for both the radiosensitivity
and chemosensitivity enhancement of malignant gliomas.
Dr. Alexandros Bouras received his Medical Degree (MD) from the University of Athens Medical
School in Athens, Greece. He completed his residency in General Surgery at
Metaxa Cancer Hospital in Piraeus, Greece, and his residency in Neurological Surgery at Tzanio
General Hospital in Piraeus, Greece. He is currently a Senior Research Scientist
and the Lab Manager of the Brain Tumor Nanotechnology Laboratory at the
University of Pittsburgh Medical Center Hillman Cancer Center in the Department
of Neurosurgery. Dr. Bouras’ main research interests focus on the application of magnetic hyperthermia therapy and photodynamic
therapy for the targeted imaging and therapy of patient-based glioma models
both in cell culture and rodent models. Moreover, he is actively
investigating the delivery of therapeutics in the brain by convection-enhanced
delivery, as well as the use of focused ultrasound for either the sonodynamic
therapy of malignant brain tumors or blood–brain barrier opening for the enhanced
systemic delivery of therapeutics in the brain. Finally, he is heavily involved
in the study of combination therapies for both the radiosensitivity
and chemosensitivity enhancement of malignant gliomas.